VRNA Profile
Verona Pharma plc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. The company's primary focus is on advancing novel treatments for conditions such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
Verona Pharma's lead product candidate, ensifentrine, represents a breakthrough in respiratory care. This inhaled compound functions as a dual inhibitor of phosphodiesterase (PDE) 3 and PDE4 enzymes, offering both bronchodilation and anti-inflammatory effects. Ensifentrine is currently undergoing Phase 3 clinical trials, where it is being evaluated for its efficacy and safety in treating the aforementioned respiratory conditions.
The company is developing ensifentrine in three distinct formulations to enhance its utility and accessibility: a nebulizer solution, a dry powder inhaler, and a pressurized metered-dose inhaler. This range of delivery methods aims to cater to different patient preferences and clinical needs, providing flexibility in managing respiratory diseases.
Established in 2005 and headquartered in London, United Kingdom, Verona Pharma plc is at the forefront of respiratory medicine innovation. The company’s commitment to addressing unmet needs in respiratory disease management underscores its strategic vision and dedication to improving patient outcomes through cutting-edge therapeutic solutions.
|
